CT Body Composition of Sarcopenia and Sarcopenic Obesity: Predictors of Postoperative Complications and Survival in Patients with Locally Advanced Esophageal Adenocarcinoma.
body composition
computed tomography
esophageal cancer
sarcopenia
sarcopenic obesity
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
06
05
2021
revised:
06
06
2021
accepted:
08
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
To assess the impact of body composition imaging biomarkers in computed tomography (CT) on the perioperative morbidity and survival after surgery of patients with esophageal cancer (EC). Eighty-five patients who underwent esophagectomy for locally advanced EC after neoadjuvant therapy between 2014 and 2019 were retrospectively enrolled. Pre- and postoperative CT scans were used to assess the body composition imaging biomarkers (visceral (VAT) and subcutaneous adipose tissue (SAT) areas, psoas muscle area (PMA) and volume (PMV), total abdominal muscle area (TAMA)). Sarcopenia was defined as lumbar skeletal muscle index (LSMI) ≤38.5 cm Preoperatively, sarcopenia was identified in 58 patients (68.2%), and sarcopenic obesity was present in 7 patients (8.2%). Sarcopenic patients were found to have an elevated risk for the occurrence of major complications (OR: 2.587, CT body composition imaging biomarkers can identify high-risk patients with locally advanced esophageal cancer undergoing surgery. Sarcopenic patients have a higher risk of major complications, and patients with sarcopenic obesity are more prone to postoperative pneumonia. Sarcopenia and sarcopenic obesity are both subsequently associated with a prolonged hospitalization. Low preoperative muscle mass and its decrease during the postoperative follow-up are associated with lower DFS and OS.
Sections du résumé
BACKGROUND
BACKGROUND
To assess the impact of body composition imaging biomarkers in computed tomography (CT) on the perioperative morbidity and survival after surgery of patients with esophageal cancer (EC).
METHODS
METHODS
Eighty-five patients who underwent esophagectomy for locally advanced EC after neoadjuvant therapy between 2014 and 2019 were retrospectively enrolled. Pre- and postoperative CT scans were used to assess the body composition imaging biomarkers (visceral (VAT) and subcutaneous adipose tissue (SAT) areas, psoas muscle area (PMA) and volume (PMV), total abdominal muscle area (TAMA)). Sarcopenia was defined as lumbar skeletal muscle index (LSMI) ≤38.5 cm
RESULTS
RESULTS
Preoperatively, sarcopenia was identified in 58 patients (68.2%), and sarcopenic obesity was present in 7 patients (8.2%). Sarcopenic patients were found to have an elevated risk for the occurrence of major complications (OR: 2.587,
CONCLUSION
CONCLUSIONS
CT body composition imaging biomarkers can identify high-risk patients with locally advanced esophageal cancer undergoing surgery. Sarcopenic patients have a higher risk of major complications, and patients with sarcopenic obesity are more prone to postoperative pneumonia. Sarcopenia and sarcopenic obesity are both subsequently associated with a prolonged hospitalization. Low preoperative muscle mass and its decrease during the postoperative follow-up are associated with lower DFS and OS.
Identifiants
pubmed: 34208070
pii: cancers13122921
doi: 10.3390/cancers13122921
pmc: PMC8230687
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Clin Nutr. 1999 Mar;69(3):373-80
pubmed: 10075319
Cancers (Basel). 2010 Jun 28;2(3):1379-404
pubmed: 24281163
Medicine (Baltimore). 2018 Dec;97(52):e13878
pubmed: 30593194
Curr Oncol Rep. 2016 Oct;18(10):62
pubmed: 27541923
Cancers (Basel). 2020 Oct 12;12(10):
pubmed: 33053623
Cancers (Basel). 2020 Nov 04;12(11):
pubmed: 33158224
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Thorac Dis. 2014 May;6 Suppl 3:S289-97
pubmed: 24876933
N Engl J Med. 2019 Jan 10;380(2):152-162
pubmed: 30625052
J Gastrointest Surg. 2015 Apr;19(4):587-93
pubmed: 25652343
Surg Oncol Clin N Am. 2019 Apr;28(2):177-200
pubmed: 30851822
Eur J Surg Oncol. 2017 Feb;43(2):478-484
pubmed: 28024944
Dis Esophagus. 2013 Aug;26(6):587-93
pubmed: 23237356
Multimed Man Cardiothorac Surg. 2021 Apr 9;2021:
pubmed: 33914420
Korean J Radiol. 2019 Feb;20(2):205-217
pubmed: 30672160
Langenbecks Arch Surg. 2006 Sep;391(5):455-60
pubmed: 16896830
Ann Surg. 2006 Feb;243(2):204-11
pubmed: 16432353
Z Gastroenterol. 2019 Mar;57(3):336-418
pubmed: 30861559
World J Surg Oncol. 2016 Dec 8;14(1):304
pubmed: 27927246
Abdom Radiol (NY). 2019 May;44(5):1907-1916
pubmed: 30694368
Obesity (Silver Spring). 2012 Oct;20(10):2101-6
pubmed: 22310233
Surg Endosc. 2005 Jan;19(1):40-2
pubmed: 15772875
Cancers (Basel). 2020 Dec 31;13(1):
pubmed: 33396388
Nat Rev Endocrinol. 2012 Apr 03;8(8):457-65
pubmed: 22473333
Br J Anaesth. 2015 Jan;114(1):32-43
pubmed: 25231768
Cancer Imaging. 2019 Dec 3;19(1):82
pubmed: 31796090
Int J Cancer. 2014 Sep 1;135(5):1220-8
pubmed: 24515930
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Pulm Pharmacol Ther. 2013 Aug;26(4):412-9
pubmed: 22634305
J Surg Res. 2017 May 1;211:137-146
pubmed: 28501109
Ann Oncol. 2010 May;21 Suppl 5:v46-9
pubmed: 20555101
Eur Radiol. 2016 May;26(5):1359-67
pubmed: 26334504
Eur Radiol. 2014 May;24(5):998-1005
pubmed: 24535076
Ann Surg. 2011 Jul;254(1):67-72
pubmed: 21532466
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
J Clin Oncol. 2006 Sep 10;24(26):4277-84
pubmed: 16963730
Gut. 2020 Sep;69(9):1564-1571
pubmed: 32606208
Ann Surg Oncol. 2015 Dec;22(13):4432-7
pubmed: 25862583
Clin Nutr. 2018 Aug;37(4):1101-1113
pubmed: 28734552
Eur Respir J. 2010 Dec;36(6):1330-6
pubmed: 20351023
Cancers (Basel). 2020 Feb 04;12(2):
pubmed: 32033150
Colorectal Dis. 2015 Nov;17(11):O256-64
pubmed: 26194849